Исследование взаимодействия молекулы ДНК с двуядерными координационными соединениями платины в растворе
Диссертация
Петербургской химико-фармацевтической академии. Такие исследования могут дать представление и о конформационных свойствах молекулы ДНК. Они актуальны не только потому, что ДНК является важнейшей биологической макромолекулой. В растворе она представляет собой полиион, обладающий высокой плотностью заряда и чрезвычайно большой термодинамической жесткостью. Поэтому взаимодействие такой макромолекулы… Читать ещё >
Список литературы
- Zamenhof S., Brawermann G., Chargaff E. On the desoxypentose nucleicacids from several microorganisms, Biochim. Biophys. Acta, 9, 402−405 (1952).
- Leslie A.G.W., Arnott S., Chandrasekaran R., Ratliff R.L. Polymorphism of
- DNA double helices, J. Mol Biol., 143, 49−72 (1980).
- Кантор Ч. и Шиммел П., Биофизическая химия, т.1, М: Мир, 1984
- Lewi it М. How many base-pair per turn does DNA have in solution and inchromatin? Some theoretical calculations, Proc. Nat. Acad. Sci., USA 75, 640−644(1978)
- Calladine C.R. Mechanism of sequence-dependent stacking of bases in B
- DNA J.Mol.Biol., 161, 343−352 (1982).
- Dikerson R.E. Base sequence and helix structure variation in B-and A-DNA
- J.Mol.Biol., 166, 343−352 (1983).
- Fuller W., Wilkins M.H.F., Hamilton H.R., Arnott S. The molecular configuration of deoxyribonucleic acid IV. X-Ray difraction study of the Aform J.Mol.Biol., 12, 60−80 (1965).
- Conner B.N., Takano Т., Tanada S., Itakura K., Dickerson R.E. The molecularstructure of d (CpCpGpG), a fragment of right-handed double helical A-DNA, Nature 295,294−299 (1982).
- Wang H.J., Fujii S., Boom J.H. van Rich A. Molecular structure of the octamer d (GGCCGGCC): modified A-DNA, Proc. Nat. Acad. Sci. USA, 79, 3968−3972 (1982).
- Shakked Z., Rabinovich D., Cruse W.B.T., Egert E., Kennard O., Sala G., Salisbury S.A., Viswamitra M.A. Crystalline A-DNA: The X-ray analysis of the fragment d (G-G-T-A-T-A-C-C), Proc. Roy. Soc. London Ser. B, 231, 479−487(1981).
- Shakked Z., Kennard O. The A-form of DNA In: A. McPherson and F. Jurnak, eds., Structural biology, John wiley and Sons, New York, 1983.
- Zimmerman S.B., Pheiffer B.H. A direct demostration that the ethanol-induced tranition of DNA is between the A and B form: an X-ray diffraction study, J. Mol.biol., 135, 1023−1027 (1979).
- Arnott S., Hukins D.W.L. Optimised parameters for A-DNA and B-DNA Biochem. Biophys. Res Commun., 47, 1504−1510 (1972)
- Wing R. Drew H., Takano T., Broka C., Tanaka S., Itakura K., Dickerson R.E. Crytal structure analysis of a complete turn of DNA, Nature 287, 755 758 (1980).
- Klug A., Jack A., Vicwamitra M.A. Kennard O., Shakked Z., Steitz T.A. A hypothesis on a specific sequence-dependent conformation of DNA and its relation to the binding of the lac-repressor protein, J.Mol.Biol., 131, 669−680 (1979).
- Shindo H. Zimmerman S.B. Sequence-dependent variations in the backbone geometry of a synthetic DNA fibre, Nature 283, 690−691 (1980)
- Shindo H., Simpson R.T. Cohen J.S. An Alternating conformation characterizes phosphodiester backbone of ploy a (A-T) in solution, J. Biol. Chem, 254, 8125 -8128 (1979).
- Patel D.J. Canuel L.L., Pohl F.M. «Alternating B-DNA» conformation for the oligo (dG-dC) duplex in high-salt solution, Proc.Nat. Acad. Sci. USA, 76, 2508−2511 (1979).
- Schefler I.E., Elson E.L., Baldwin R.L., Helix formation by d (A-T) oligomers. I. Hairpin and straight-chain helices, J. Mol Biol., 36, 291−304 (1968).
- Lutter L.C. Deoxyribonuclease I produces staggered cuts in the DNA ofchromatin, J. Mol. Biol., 117, 53−69 (1977).
- Riggs A.D., Lin S.-Y., Wells R.D. lac repressor binding to synthetic DNAs of defined nucleotide sequence, Proc. Nat. Acad. Sci. USA, 69, 761−764 (1972).
- Arnott S., Seising E., The Conformation of C-DNA, J. Mol. Biol., 98, 265 269 (1975)
- Brahms J., Pilet J., Lan T.-T.P., Hill L.R. Direct evidence of the C-like formof sodium deoxyribonucleate, Proc.Nat. Acad Sci. USA, 70, 3352−3355 (1973).
- Arnott S., Chandrasekara R., Hukins D.W.L., Smith P.J.C., Watts L., Structural details of a double-helix observed for DNA s containing alternating purine-pyrimidine sequences, J.Mol. Bio., 88, 523−533 (1974).
- Mahendrasingam A., Rhodes N.J., Goowin D.C., Nave C., Pigram W.J., Fuller W., Brahms J.,., Vergne J. Conformational transitions in oriented fibers of the synthetic polynucleotide poly d (AT0.-poly[d (AT)] double helix., Nature 301, 535−537 (1983).
- Мокульский M.A., Капитонова K.A., Мокульская Т. Д. Вторичная структура ДНК фага Т2 Мол. Био., 6 (1974).
- DeConti R, Toftness В, Lange R, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973−33: 1310−5
- Gormley P, Bull J, LeRoy A. et al. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 1979- 25:351−7
- Belt R, Himmelstein K, Patton T, et al. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinumd!). Cancer Treat Rep 1979- 63: 1515−21
- Judson I, Kelland IR. New developments and approaches in the platinum arena. Drags 2000- 59 Suppl. 4: 29−36
- Ronbseerg, B., van Camp, L. and Kirgan, T. (1965) Nature 205, 698.
- Reedijk, J. (1992) Inorg. Chim. Acta 198−200, 873−881
- Comess, K. M., and Lippard. S. J- Molecular Aspects of platinum-DNA In:. S. Neidle and M. Waring, editors. Molecular Aspects of Anticancer Drug-DNA Interactions (eds), Macmillan, London.. (1993), Vol 1. pp. 134 168
- Pinedo, H. M. and Schornagel, J. H. (Eds.) (1996) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Plenum, New York/London.
- Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000- 59 Suppl. 4: 29−36
- Duffiill S, Robinson B. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997- 33: 161−83
- Extra J, Marly M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998- 25: 13−22
- Himmelstein K, Patton T, Belt R, et al. Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther 1981- 29: 658−64
- Vermorken J, van der Vijgh W, Klein I, et al. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 1984- 68: 505−13.
- Egorin MJ, Van Echo DA, Olman EA, et al. Prospective of validation of a pharmacologically-based dosing scheme for the cis-diamminedichloroplatin (II) analogue cis-diammine-cyclobutanedicarboxylato platinum (II). Cancer Res 1985- 45: 6502−6
- Calvert AH, Newell DR. Gumbrell LA. et al. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function. J Clin Oncol 1989- 7: 1748−56
- Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Nat! Cancer Inst 1995- 87: 573−80
- Jodrell D, Egorin M, Canetta R. et ai. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992- 10: 520−8
- Reyno L, Egorin M, Canetta R. et al. Impact of cyclophos-phamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 1993- 11: 1156−64
- O’DwyerPJ. Hamilton TC. YaoK-S.etal. Cellular pharmaco-dynamics of anticancer drugs. In: Schilsky R. Milano G, Ra-tain M, editors. Cancer pharmacology. 1996: 329−62
- Reed E, Ozols RF, Tarone R. et al. Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sei USA 19S7: 84: 5024−8
- Schellens JHM, Ma J, Planting ASTL, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes, and tumor response in patients with solid tumors. Br J Cancer 1996- 73: 1569−75
- Schellens JHM, Ma J, Planting ASTL, et al. Adaptive intrapati-ent dose escalation of cisplatin. Proc Am Soc Clin Oncol 1996- 15: 178.
- Wolf W., Monaka R.C., Lex F.K.V., J. Clin. Hematol. Oncnl., 1977,7, 741, p. 79
- Taylor D.M., Biochim., 1978, 60, p. 949.
- Chu, G. (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair J. Biol. Chem, Jan 1994- 269: 787 790
- Hills CA. Kelland LR, Abel G. et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989: 59: 527−34
- Johnson SW. Ferry KV. Hamilton TC. Recent insights into platinum drug resistance in cancer. Drag Resist Updates 1998: 1: 243−54
- Godwin AK, Meister A. O’Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992:89:3070−4
- O’Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosemberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott Publishers, 1997: 418−32
- Izquierdo MA, Scheffer GL, Flens MJ, et al. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996- 19: 191−7
- Izquierdo MA, van der Zee AC, Vermorken JB, et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995: 87: 1230−7
- Reed E, Ozols RF, Tarone R, et al. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sei USA 1987- 84- 5024−8
- Ma J, Verweij J, Planting ASTL, et al. Current sample handling methods for measurement of platinum-DNA adducts in leukocytes in man lead to discrepant results in DNA adduct levels and’DNA repair. Br J Cancer 1995- 71:512−7
- Schellens JHM, Ma J, Planting ASTL, et al. Relationship between the exposure to cisplatin, DNA adduct formation in leukocytes, and tumor response inpatients with solid tumors. Br J Cancer 1996- 73: 1569−75
- Reed E. Platinum-DNA adduct. nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998- 24: 331−44
- Dabholkar M, Viommet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994- 94: 703−8
- Dabholkar M. Berger MS, Vionnet JA, et al. Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995- 55: 1261−6
- Crul M, Schellens JHM. Beijnen JH, et al. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997- 23: 341−66
- Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996:56:3087−90
- Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998- 4: 1−6
- Brown R, Hirst GL, Gallagher WM, et al. hMLHl expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997- 15: 45−52
- Loehrer P. Einhorn L. Drugs five years later. Cisplatin. Ann Intern Med 1984:100:704−13
- Cvitkovic E. Spaulding J. Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119 875): therapeutic index in an animal model. Cancer 1977- 39: 1357−61
- Hayes D. Cvitkovic E. Golbey R, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by man-nitol diuresis. Cancer 1977: 39:1372−81
- Gralla RJ. Osoba D. Kris MG. et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society Clinical Oncology. J Clin Oncol 1999- 17:2971−94.
- McMahon SB. Priestley JV. Peripheral neuropathies and neu-rotrophic factors. Animal models and clinical perspectives. Curr Opin Neurobiol 1995:5:616−24.
- Глинка H.A., Общая химия, M., 1965, с. 567−576.
- Черняев И.И., Комплексные соединения переходных металлов, М., Наука, 1973, с. 15−173.
- Гринберг А.А., Введение в химию комплексных соединений.
- Karter S.K., cis-platin: current states and new developments, New York: Acaf. press, 1980.
- Переводчикова Н.И. и др., Средство для лечения злокачественныхопухолей яичко и рака яичника «платин», опубл. 30.03.91, бюл. 14.
- Николенко О., Диплом ЛГУ, 1992.
- Thompson A.J., Williams R., Resbovas I.P., Structure and Bonding, 1971, 1, 11
- Cleare M. S., Clin J., Hematve Oncol., 1977, 17, 1.
- Хаджигиадис H., Соединения платины в хемотерапии рака, М.,
- Наука и человечество, 1987
- Иванов В.Б., Метинская Т. К., Чельцов П. А., Щелоков Р.Н., Известия
- АН СССР, Серия биологическая, 1981, 4, с. 551−557
- Jundgust W., Lippard S., Coord. Chem. Rew., 1990, 100, p. 293
- Иванов В.Б., Чельцов П. А., Щелоков P.H., Известия АН СССР,
- Серия биологическая, 1981, 1, с. 104−115
- Иванов В.Б., Быстрова Е. И., Ларина Л. П., Стеценко А.И., Адамов
- О.Н., Алексеева Г. М., Яковлев К. И., Дмитриева Е. С., Известия АН СССР, Серия биологическая, 1988, 5, с. 746−752.
- Giovanni Natilea and Mauro Colucciab Current platinum compounds status of trans- in cancer therapy COORDINATION CHEMISTRY REVIEWS 2001,216−217:1:383 -410
- Andrew, P. A- Mann S.C. — Velury, S.B. In platinum and other metal coordination compounds in cancer chemotherapy- Nicolini, M., Ed.- Martinus Nijhoff Publishing: Boston, 1988- pp 248−254.
- Gately, D.P.- Howell, S.B. Br.J. Cancer 1993, 67, 1171−1176.
- Tal Peleg-Shulmana, Dan Gibsona, b, Rivka Cohenc, Robert Abrad and Yechezkel Barenholzc Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance BIOCHIMICA ET BIOPHYSICA ACTA/BIOMEMBRANES 2001,1510:1−2:278−291
- Stefanov V.E., Tulub A.A. and. Kutin A. A The effect of the chain length ofpolynucleotides on theirbinding with platinum complexes INTENRATIONAL JOURNAL OF BIOLOGICAL
- MACROMOLECULES 1999,26:2−3:161−166
- Peter Rauko, Ladislav Novotny, Ima Dovinova, Luba Hunakova, Thomas
- Szekeres and Hiremagalur N. Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine Jayaram European Journal of Pharmaceutical Sciences, 2001, 12:4:387−394
- Witkin, E.M. Proc.Natl.Acad.Sci. U.S.A. 1967, 57,1275−1279.
- Adler, H.I.- Hardigree, A.A. Rad.Res.1965, 25, 92−102
- Rosenkranz, H.S. — Garro, A.J.- Levy, J .A.- Carr, H.S. Biochim. Biophys. Acta 1966, 114,501−515.
- Reslova, S. Chem. Biol. Interact. 1971, 4, 66−70.
- Fichtinger-Schepman AM. van der Veer JL. den Hartog JH. et al. Adducts of the antitumour drug cis-diamminedichloro-platinum (II) with DNA: formation, identification and quanti-tation. Biochemistry 1985- 24: 707−13
- Comess KM. Lippard SJ. Molecular aspects of platinum-DNA interactions. In: Neidle S. Waring M, editors. Molecular aspects of anticancer drug-DNA interactions. Vol 1. London: The Macmillan Press Ltd, 1993: 134−68.
- Harder H., Rosenberg B., Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in virtro. Int J Cancer. 1970 15−6(2):207−216.
- Sheibabi N., Biochem., 1989, 28, p. 3120.108.01inski R, Briggs RC, Basinger M, Jones MM. 1992 Effectiveness of chemical agents in removing platinum from DNA isolated from cisplatin-treated HL-60 cells. ActaBiochim Pol. 39(4):327−334.
- Akaboshi, M.-Kawai, K- Maki, H.- Akuta, K- Ujeno, Y.- Miyahara, T.Jpn. J. Cancer Res. 1992,83, 522−526.
- Beck, D.J.-Brubaker, R.R., J. Bacteriology 1973, 116, 1247−1252
- Drobnik, J.- Urbankova, M.- Krekulova, A. Mutat.Res.1973, 17, 13−20.
- Markham, B.E.- Brubaker, R.R.J. Bacteriol. 1980, 143, 455−462.
- Brouwer, J.- van de Putte, p.- Fichtinger-Schepman, A.M.J.- Reedijk, J. Proc.Natl.Acad.Sei.U.S.A. 1981, 78, 7010−7014.
- Beck, D.J.- Popoff, S.- Sancar, A.- Rupp, W.D. Nucleic Acids Res. 1985,13, 7395−7412.
- Fram, R.J.- Cusick, P. S.- Wilson, J.M.- Marinus, M.G.Mol. Phamacol. 1985,28,51−55.
- Popoff, S.C.- Beck, D.J.- Rupp, W.D. Mutat.Res. 1987,183,129−137.
- Wang, K.- Lu, J.- Li, R. Coord. Chem. Rev. 1996.151, 53−88.
- Speelmans, G.- Sips, W.H.H.M.- Grisel, R.J.H.- Staffhorst, R.W.H.M.- Fichtinger-Schpeman, A.MJ.- Reedijk, J.- de Kruijff, B. Biochim. Biphys. Acta 1996, 1283,60−66.
- Speelmans, G.- Staffhorts, R.W.H.M.- Versluis, K.- Reedijk, J.- de Kruijff, B. Biochemistry 1997,36, 10 545−10 550.
- Kopt-Maier, P. Muhlhausen, S.K. Chem.Biol.Interact. 1992, 82, 295−316.
- Zeng, H.- Wang, B.- Zhang, Y.- Wang, K. Thermochim. Acta 1995, 265, 31−38.
- Korst, A.E.C.- Eelting, C.M.-Vermorken, JB.- van der Vijgh, WJ.F. Eur. J. Cancer 1997,33, 1425
- Treskes, M.- van der Vijgh, W.J.F. Cancer Chemother. Pharmacol. 1993, 33.93.
- Reedijk, J. Inorg. Chim. Acta 1992,198−200,873.
- Sherman, S. E., Gibson, D., Wang, A. H.-J. and Lippard, S. J. (1988) J. Am. Chem.Soc. 110, 7368−7381
- Coll M, Sherman SE, Gibson D, Lippard SJ, Wang AH. (1990) Molecular structure of the complex formed between the anticancer drug cisplatin and d (pGpG): C222(l) crystal form. J Biomol Struct Dyn 8,315−330
- Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 270, 1842−1845.
- Fichtinger-Schepman, A. M., van der Veer, J. L., den Hartog, J. H. J., Lohman,.
- Corda, Y., Anin, M.-F., Leng, M. and Job, D. (1992) Biochemistry 31, 1904−1908
- Anderson, K. S. (1979) Mutation Res. 67, 209−214.
- Bancroft, D. P., Lepre, C. A. and Lippard, S. J. (1990) J. Am. Chem. Soc. 112, 6860−6871.
- Sip M, Schwartz A, Vovelle F, Ptak M, Leng M (1992) Distortions induced in DNA by cis-platinum interstrand adducts. Biochemistry. 31,2508−2513.
- Bradley LJ, Yarema KJ, Lippard SJ, Essigmann JM. (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum (II). Biochemistry 32,982−988.
- Eastman A. Barry MA. Interaction of trans-diammine-dichloroplatinum (II) with DNA: formation of monotunc-tional adducts and their reaction with glutathione. Biochemistry 1987:26:3303−7
- Szymkowski DE, Yarema K. Essigmann JM. et al. An in-trastrand d (GpG) platinum crosslink in duplex MI3 DNA is refractory to repair by human cell extracts. Proc Natl Acad Science USA. 1992: 89: 10 772−6 .
- Zwelling LA. Anderson T. Kohn KW. DNA-protem and DNA inlerstrand cross-linking by cis- and trans-platinum (II) diamminedichloride in L1210mouse leukemia cells and relation to cylotoxicity. Cancer Res 1979: 39 (2 Pt I): 365−9 .
- Eastman A, Jennerwein MM, Nagel DL. (1988) Characterization of Afunctional adducts produced in DNA by trans-diamminedichloroplatinum (II). Chem Biol Interact. 67,71−80.
- Iwamoto, M., Mukunda, S.J. and Marzilli, L.G. (1994), J.Am.Chem.Soc. 116,6238−6244.
- Chao, C.C.K, Huang, S.L., Lee, L.Y. and Lin-Chao, S. (1991) Biochem. J. 277,875−878.
- Calsou, P., Frit, P. And Salles, B. (1992) Nucleic Acids Res. 20,6363−6368.
- Herman, F., Kozelka, J., Sloven, V., Guittet, E., Girault, J.-P., Huynh-Dinh, T., Igolen, J., Lallemand. J.-Y. And Chottard, J.-C. (1990) Eur. J. Biochem. 194, 119−133.
- Bellon SF, Coleman JH, Lippard SJ. (1991) DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum (II). Biochemistry 30,8026−8035.
- Huang H. Zhu L. Reid BR, et al. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995: 270: 1842−5
- Comess, K. M., and Lippard. S. J- Molecular Aspects of platinum-DNA In:. S. Neidle and M. Waring, editors. Molecular Aspects of Anticancer Drug-DNA Interactions (eds), Macmillan, London.. (1993), Vol 1. pp. 134 168.
- Taylor D.M., Biochim., 1978, 60, p. 949
- Yang, D., van Boom, S.S.G.E, Reedijk, J., van BoomJ.H., and Wand, A.H.-J. (1995) Biochemistry 34,12, 912−12,920.
- Rice, J.A., Crothers, D.M., Pinto, A.L. and Lippard, SJ.(1988) Proc. Natn. Acad. Sei. U.S.A.85 4158−4161.
- Bancroft, D. P., Lepre, C. A. and Lippard, S. J. (1990) J. Am. Chem. Soc. 112, 6860−6871.
- Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 270, 1842−1845.
- Paquet F, Perez C, Leng M, Lancelot G, Malinge JM. (1996) NMR solution structure of a DNA decamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum (II). J Biomol Struct Dyn. 14,67−77.
- Guan Y, Gao YG, Liaw YC, Robinson H, Wang AH. (1993) Molecular structure of cyclic diguanylic acid at 1 A resolution of two crystal forms: self-association, interactions with metal ion/planar dyes and modeling studies. J Biomol Struct Dyn. 11,253−276
- Wang AH, Quigley GJ, Kolpak FJ, Crawford JL, van Boom JH, van der Marel G, Rich A. (1979) Molecular structure of a left-handed double helical DNA fragment at atomic resolution.Nature. 282, 680−686.
- Malfoy, В.- Hartman, В.- Leng. M. (1981) Nucl. Acid. Res. 9, 5659−5669
- Ushay, H.M.- Santella, R.M.- Caradonna, J.P.- Grunberger, D. and Lippard S.J. (1982) Nucl. Acid. Res. 10, 3573−3 587 161. van Boom, S.S.G.E., Yang, D." Reedijk, J., van der Marel, G.A. and Wand, A.H.-J. (1996) J. Biomolec. Struct. Dyn 13, 989−998.
- Касьяненко H.A., Фрисман, Э.В., Валуева C.B., Сморыго Н. А., Дьяченко С. А., Молекуляр. Биология. 1995, 29, 345−353.
- Касьяненко Н.А., Фрисман, Э.В., Карымов М. А., Сморыго Н. А., Дьяченко С. А., Молекуляр. Биология. 1995, 29, 580−588.
- Касьяненко Н.А., Николенко О. В., Прохорова С. А., Дьяченко С. А., Сморыго Н. А., Ивин Б. А., Фрисман, Э.В., Молекуляр. Биология. 1997, 31,287−292.
- Weis, R.B.- Christian, М.С. Drugs 1993, 46, 360−377 166.Lebwohl, D.- Canetta, R. Eur.J. Cancer 1998 34 1522−1534
- Kelland, L.R.- Abel, G.- McKeage, M.J.- Jones, M.- Goddard, P. M.- Valenti, M. Murrer, В .A. Harrap, K.R. Cancer Res. 1993, 53 2581−2586.
- Farrell, N.- Ha, T.T.B.- Souchard, J.P.- Wimmer, F.L.Johnson, N.P. J. Med. Chem. 1989, 32, 2240−2241.
- Farrell, N.- Kelland, L.R.- Roberts, J.D.- Van Beusichem.M. Cancer Res. 1992, 52, 5065−5072.
- Van Beusichem, M.- Farrell, N. Inorg. Chem. 1992,31, 634−639
- Coluccia, M.- Nassi, A.- Loseto, F.-Boccarelli, A.- Mariggio, M.A.- Giordano, D.- Intini, F.P.- Caputo, P.- Natile, GJ. Med. Chem. 1993,36, 510−512.
- Mellish, К J.- Barnard, C.F.J.- Murrer, B.A.- Kelland, L. R Int.-.J. Cancer 1995,62,717−723.
- Kelland, L.R.- Barnard, C.F.J.- Evans, I.G. Murrer, B.A.-Theobald, B.R.C.- Wyer, S.B.- Goddard, P.M.- Jones, M.- Valenti, M.- Bryant, A.- Rogers, P.M.- Harrap, K.R. J. Med. Chem. 1995, 38,3016−3024.
- Wu, P.K.- Kharatishvili M.- Qu Y.- Farrell N.- J. Of Inorg. Che. 1996, 63, 9−18.
- Farrell N., Appleton T.G., RobertsJ.D. Soares Fontes, A.P., Skov, K.A., Wu P., Zou Y., Biochem., 1995, 34, 15 480−15 486.
- Amo Ochoa P., Gonzalez, V.M., Perez, J.M., Masaguer J.R., Alonso C., Navarro-Ranninger C., J. Of Inorg. Biohem., 1996, 64, 287−289.
- Peg, A.E.- Biochem. 1988, 234, p 249.
- Furestein B.G.- Pattabhiraman, N.- Marton L.J.- Proc. Nalt. Acad. Sci. USA, 1986, 83 p. 5948.
- Яцимирский К.Б., Стеценко А. И. и др., Доклад АН СССР, 1979,245, 2, с. 385
- Стеценко А.И. и др., Координационная химия, 1980, 6, 9, с. 1455
- Beek W. and others, Y. Naturforsch, 1976, 31, p. 932
- Mollis S.Z. and others, Platinum and other metal coordinationcompounds in cancer chemotherapy, Italy, 1987, p. 538
- Passini A., Angew Chem., 1987, 99, p. 632
- Цветков B.H., Эксин B.E, Френкель С.Я."Структура макромолеку врастворе" М, Наука, 1964 гл 2 с 93−97. 93−97, 105−106, 141−142
- Касьяненко H.A., Фрисман Э. В., Валуева C.B., Сморыго H.A.,
- Дьяченко С.А., Молекуляр. биология, 1995,29, с. 345−353
- Касьяненко H.A., Фрисман Э. В., Карымов М. А., Сморыго H.A.,
- Дьяченко С.А., Молекуляр. биология, 1995, 29, с. 580−588
- Касьяненко H.A., Николенко О. В., Прохорова С.А., Дьяченко
- С.А., Сморыго H.A., Ивин Б. А., Фрисман Э. В., Молекуляр. биология, 1997, 31, 2, с. 287−292
- Касьяненко H.A., Бартошевич С. Ф., Фрисман Э. В., Молекуляр.биолгия, 1985, 19, с. 1386ненко H.A., Фрисман Э. В., Кленин С. И., Быкова E.H., Кочеткова И. С., Высокомолекуляр. соединения, 1987, 29, с. 1129
- Фрисман Э.В., Щагина Л. В., Воробьев В. И., биогеология, 1965, 2, с. 189
- Rosenberg В., Van Camp L., Trosko J. E., Mansour V. H. // Nature. 1969. V. 222. P. 385−386.
- Cisplatin: Current Status and New Development / Eds. Prestayko A. W., Crooke S. T., Carter S. K. N. Y.: Acad. Press,. 1980. P. 527.
- Яковлев К. И., Рожкова H. Д., Стеценко А. И. // Журнал неорганической химии. 1991. Т. 36. С. 120−127.
- Farell N. Р., Yun Qu, Hacker M. P. // J. Med. Chem. 1990. V. 33. P. 2179−2184.
- Иванов В. Б., Быстрова Е. И., Яковлев К. И., Рожкова Н. Д., Стеценко А. И., Адамов О. М. // Известия акад. наук. Сер. Биологическая. 1992. Т. 6. С. 898−907.
- Rosenberg В. // Plat. Met. Rev. 1971. V. 15. P. 42−51.
- Lippard S. J. //Pure and Appl. Chem. 1987. V. 59. P. 731−742.
- Jamienson E.R., Lippard S.J. // Chem. Rev. 1999. V. 99. P. 2467−2498.
- Furlan D. // Chem. Biol. Interact. 1977. V. 16. P. 1.
- Касьяненко H. А., Валуева С. В., Сморыго H. А., Дьяченко С. А., Фрисман Э. В. // Молекул. Биол. 1995. Т. 29. С. 354 353 .
- Касьяненко H. А., Карымов M. А., Дьяченко С. А., Сморыго Н. А., Фрисман Э. В. // Молекул. Биол. 1995. Т. 29. С. 585 594.
- Courtois Y., Fromageot P., Gushlbauer W. // Eur. J. Biochem. 1968. V. 6. P. 493−501.
- Касьяненко H. А., Бартошевич С. Ф., Фрисман Э. В. // Молекул. Биол. 1995. Т. 29. С. 585−594.
- Reinert К. Е. // Biophys. Chem. 1981. Y. 13. P. 1 14.
- Kasyanenko N., Arikainen N., Frisman E. // Biophys. Chem. 1998. V. 70. P. 93 100.
- Kasyanenko N. A., Zanina A. V., Nazarova О. V., Panarin E. F. /'/' Langmuir. 1999. V. 15. P. 7912−7917.